BackgroundCheck.run
Search For

Zhenhua XuNorth Wales, PA

Zhenhua Xu Phones & Addresses

North Wales, PA   

1434 Sugartown Rd, Berwyn, PA 19312   

Paoli, PA   

Malvern, PA   

Chester, PA   

Education

Degree: Associate degree or higher

Emails

j***[email protected]
Get Report
Control this profile

Mentions for Zhenhua Xu

Zhenhua Xu resumes & CV records

Resumes

Zhenhua Xu Photo 18

Director Clinical Pharmacology

Location:
1434 Sugartown Rd, Berwyn, PA 19312
Industry:
Pharmaceuticals
Work:
Johnson & Johnson
Director Clinical Pharmacology
Education:
Central South University 1987 - 1992
Languages:
Mandarin
Zhenhua Xu Photo 19

Zhenhua Xu

Zhenhua Xu Photo 20

Zhenhua Xu

Publications & IP owners

Us Patents

Materials And Methods For Treating Juvenile Idiopathic Arthritis

US Patent:
2021034, Nov 4, 2021
Filed:
Apr 26, 2021
Appl. No.:
17/240609
Inventors:
- Horsham PA, US
Michael Clark - Warminster PA, US
Jocelyn Leu - Ambler PA, US
Zhenhua Xu - Berwyn PA, US
International Classification:
C07K 16/24
A61K 31/519
A61P 19/02
Abstract:
The present invention relates to compositions and methods utilizing anti-TNF antibodies, e.g., the anti-TNF antibody golimumab having a heavy chain (HC) comprising an amino acid sequence of SEQ ID NO:36 and a light chain (LC) comprising an amino acid sequence of SEQ ID NO:37, for use in the treatment of juvenile idiopathic arthritis (JIA), and in particular for polyarticular juvenile idiopathic arthritis (pJIA).

Materials And Methods For Improved Prediction Of Igg Therapeutic Protein Exposure

US Patent:
2021031, Oct 14, 2021
Filed:
Apr 13, 2021
Appl. No.:
17/229124
Inventors:
- Horsham PA, US
Jocelyn Leu - Ambler PA, US
Yan Xu - Lansdale PA, US
Zhenhua Xu - Berwyn PA, US
International Classification:
G01N 33/68
C07K 16/28
Abstract:
Methods for predicting pharmacokinetics of an Immunoglobulin G (IgG) therapeutic protein based on a patient's level of rheumatoid factor (RF), anti-citrullinated protein antibodies (ACPA), or RF and ACPA. Methods disclosed herein also relate to methods for determining the therapeutically effective dose of an IgG therapeutic protein based on the levels of RF, ACPA, or RF and ACPA.

Method Of Providing Subcutaneous Administration Of Anti-Cd38 Antibodies

US Patent:
2020012, Apr 23, 2020
Filed:
Oct 17, 2019
Appl. No.:
16/656569
Inventors:
- Horsham PA, US
Ivo Nnane - East Fallowfield PA, US
Donald Raible - Berwyn PA, US
Cathye Shu - Landsdale PA, US
Zhenhua Xu - Berwyn PA, US
International Classification:
A61K 9/00
A61K 31/573
A61K 38/47
C07K 16/28
A61P 37/06
Abstract:
Provided are methods of subcutaneous administration of anti-CD38 monoclonal antibodies, such as daratumumab. Also provided are methods for the treatment of autoimmune diseases with subcutaneously administered anti-CD38 monoclonal antibodies. A corticosteroid is optionally administered prior to subcutaneous administration of the anti-CD38 antibody to prevent and/or reduce systemic injection related side effects.

Isbn (Books And Publications)

Le Neologisme Et Ses Implications Sociales: [Xin Ci Yu She Hui Hu Dong Guan Xi Yan Jiu]

Author:
Zhenhua Xu
ISBN #:
2747504654

Possible Relatives

David Xu  Dawei H Xu  Da Z Xu  Dan Xu  Daniel B Xu  Denise Xu  Danny Xu  Zhenhua Li  Zhenhua Liu  Zhenhua Xie 

NOTICE: You may not use BackgroundCheck or the information it provides to make decisions about employment, credit, housing or any other purpose that would require Fair Credit Reporting Act (FCRA) compliance. BackgroundCheck is not a Consumer Reporting Agency (CRA) as defined by the FCRA and does not provide consumer reports.